blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2621282

EP2621282 - GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.02.2021
Database last updated on 16.09.2024
FormerThe patent has been granted
Status updated on  13.03.2020
FormerGrant of patent is intended
Status updated on  20.11.2019
FormerExamination is in progress
Status updated on  10.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2020/16]
Former [2013/32]For all designated states
The Regents of the University of California
1111 Franklin Street 12th Floor
Oakland, CA 94607-5200 / US
Inventor(s)01 / KAUFMAN, Daniel
3543 Greenfield Avenue
Los Angeles California 90034 / US
02 / TIAN, Jide
3618 Keystone
Los Angeles California 90034 / US
 [2013/32]
Representative(s)Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
[2020/16]
Former [2013/32]Mistry, Meeta, et al
Greaves Brewster LLP
Copa House
Station Road
Cheddar, BS27 3AH / GB
Application number, filing date11833060.428.09.2011
[2020/16]
WO2011US53732
Priority number, dateUS201161433089P14.01.2011         Original published format: US 201161433089 P
US20100387398P28.09.2010         Original published format: US 387398 P
[2013/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012050907
Date:19.04.2012
Language:EN
[2012/16]
Type: A2 Application without search report 
No.:EP2621282
Date:07.08.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2012 takes the place of the publication of the European patent application.
[2013/32]
Type: B1 Patent specification 
No.:EP2621282
Date:15.04.2020
Language:EN
[2020/16]
Search report(s)International search report - published on:US21.06.2012
(Supplementary) European search report - dispatched on:EP09.04.2014
ClassificationIPC:A01N57/00, A61K31/66, A01N37/00, A61K31/19, A61K31/197, A61K31/4465, A61K38/20, A61K39/00, A61K39/39, A61K45/06, A61P3/08, A61P3/10
[2014/19]
CPC:
A61K31/197 (EP,CN,US); A61K45/06 (EP,CN,US); A61K31/4465 (EP,US);
A61K38/2013 (EP,US); A61K39/0008 (US); A61K39/39 (US);
A61P3/08 (EP); A61P3/10 (EP); A61P5/50 (EP) (-)
C-Set:
A61K31/197, A61K2300/00 (CN,EP,US);
A61K31/4465, A61K2300/00 (US,EP)
Former IPC [2013/32]A01N57/00, A61K31/66, A01N37/00, A61K31/19
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:GABA-AGONISTEN ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT DEM STOFFWECHSELSYNDROM UND GABA-KOMBINATIONEN ZUR BEHANDLUNG ODER PROPHYLAXE VON DIABETES VOM TYP I[2013/32]
English:GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES[2013/32]
French:AGONISTES DE GABA DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS AU SYNDROME MÉTABOLIQUE ET COMBINAISONS DE GABA DANS LE TRAITEMENT OU LA PROPHYLAXIE DU DIABÈTE DE TYPE I[2013/32]
Entry into regional phase26.04.2013National basic fee paid 
26.04.2013Search fee paid 
26.04.2013Designation fee(s) paid 
26.04.2013Examination fee paid 
Examination procedure26.04.2013Examination requested  [2013/32]
10.11.2014Amendment by applicant (claims and/or description)
02.02.2016Despatch of a communication from the examining division (Time limit: M06)
08.08.2016Reply to a communication from the examining division
30.03.2017Despatch of a communication from the examining division (Time limit: M06)
05.10.2017Reply to a communication from the examining division
13.06.2018Despatch of a communication from the examining division (Time limit: M04)
15.10.2018Reply to a communication from the examining division
21.11.2019Communication of intention to grant the patent
09.03.2020Fee for grant paid
09.03.2020Fee for publishing/printing paid
09.03.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20168280.4  / EP3753410
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.02.2016
Opposition(s)18.01.2021No opposition filed within time limit [2021/12]
Fees paidRenewal fee
27.09.2013Renewal fee patent year 03
29.09.2014Renewal fee patent year 04
28.09.2015Renewal fee patent year 05
27.09.2016Renewal fee patent year 06
27.09.2017Renewal fee patent year 07
27.09.2018Renewal fee patent year 08
27.09.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.09.2011
AL15.04.2020
AT15.04.2020
CY15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
MK15.04.2020
MT15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
TR15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
IE28.09.2020
LU28.09.2020
BE30.09.2020
[2022/32]
Former [2022/27]HU28.09.2011
AL15.04.2020
AT15.04.2020
CY15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
MT15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
TR15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
IE28.09.2020
LU28.09.2020
BE30.09.2020
Former [2022/26]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
TR15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
IE28.09.2020
LU28.09.2020
BE30.09.2020
Former [2021/37]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
IE28.09.2020
LU28.09.2020
BE30.09.2020
Former [2021/36]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
LU28.09.2020
BE30.09.2020
Former [2021/27]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
LU28.09.2020
Former [2021/23]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
MC15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SI15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/10]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
PL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SK15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/09]AL15.04.2020
AT15.04.2020
CZ15.04.2020
EE15.04.2020
ES15.04.2020
FI15.04.2020
HR15.04.2020
IT15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
RO15.04.2020
RS15.04.2020
SE15.04.2020
SM15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/04]AL15.04.2020
FI15.04.2020
HR15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
RS15.04.2020
SE15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2021/01]FI15.04.2020
HR15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
RS15.04.2020
SE15.04.2020
BG15.07.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/51]FI15.04.2020
HR15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
RS15.04.2020
SE15.04.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/50]FI15.04.2020
HR15.04.2020
LT15.04.2020
LV15.04.2020
NL15.04.2020
SE15.04.2020
NO15.07.2020
GR16.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/48]FI15.04.2020
LT15.04.2020
NL15.04.2020
SE15.04.2020
NO15.07.2020
IS15.08.2020
PT17.08.2020
Former [2020/47]LT15.04.2020
NO15.07.2020
IS15.08.2020
Former [2020/46]IS15.08.2020
Documents cited:Search[Y]US2008255093  (TAM PETER Y [US], et al) [Y] 1,4-11 * columns 1, 4-11; claim - *;
 [XY]JP2009298742  (TOYO BOSEKI) [X] 1 * abstract * [Y] 4-11;
 [XI]US2010166675  (WANG QINGHUA [CA], et al) [X] 1,4,5,7-9,11 * figure 6 * [I] 6,10;
 [I]  - KAZAMA T ET AL, "Oral administration of GABA and phytosteryl ferulates prevent decreasing stressed mouse plasma adiponectin levels", FEBS JOURNAL, BLACKWELL PUBLISHING, LONDON, GB, (20100601), vol. 277, no. Suppl.1, ISSN 1742-464X, pages 70 - 71, XP009177205 [I] 1,4-11 * the whole document *
 [Y]  - UCHIDA A ET AL, "Effect of rice germ on plasma adiponectin level in C57BL/6j mice", FEBS JOURNAL, BLACKWELL PUBLISHING, LONDON, GB, (20080628), vol. 275, no. Suppl. 1, ISSN 1742-464X, page 434, XP009177219 [Y] 1,4-11 * abstract *
 [Y]  - HIROMI HAGIWARA ET AL, "The Effect of Pre-germinated Brown Rice Intake on Blood Glucose and PAI-1 Levels in Streptozotocin-induced Diabetic Rats", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, (20040101), vol. 68, no. 2, doi:10.1271/bbb.68.444, ISSN 0916-8451, pages 444 - 447, XP055110528 [Y] 1,4-11 * figure 1 *

DOI:   http://dx.doi.org/10.1271/bbb.68.444
 [Y]  - Claudio Blasi, "INFLUENCE OF BEN2lODIAZEPINES ON BODY WEIGHT AND FOOD INTAKE II'4 OBESE AND LEAN ZUCKER RATS", (20000101), pages 561 - 577, URL: http://ac.els-cdn.com/S0278584600000932/1-s2.0-S0278584600000932-main.pdf?_tid=1045a8fc-b5bf-11e3-98f4-00000aacb361&acdnat=1395931976_46e876f26166e11c8414a29a50f0be01, (20140327), XP055110410 [Y] 1,4-11 * page 570 *
 [Y]  - SQUADRITO ET AL, "Evidence that a gabaergic mechanism influences the development of obesity in obese zucker rats", PHARMACOLOGICAL RESEARCH COMMUNICATIONS, ITALIAN PHARMACOLOGICAL SOCIETY, IT, (19881201), vol. 20, no. 12, doi:10.1016/S0031-6989(88)80739-2, ISSN 0031-6989, pages 1087 - 1088, XP022220292 [Y] 1,4-11 * figure 1 *

DOI:   http://dx.doi.org/10.1016/S0031-6989(88)80739-2
 [Y]  - TEWS ET AL, "Dietary GABA decreases body weight of genetically obese mice", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 29, no. 24, doi:10.1016/0024-3205(81)90709-8, ISSN 0024-3205, (19811214), pages 2535 - 2542, (19811214), XP023734614 [Y] 1,4-11 * table 1 *

DOI:   http://dx.doi.org/10.1016/0024-3205(81)90709-8
 [IP]  - KAZUYUKI OHARA ET AL, "Oral administration of -aminobutyric acid and -oryzanol prevents stress-induced hypoadiponectinemia", PHYTOMEDICINE, vol. 18, no. 8, doi:10.1016/J.PHYMED.2011.01.003, ISSN 0944-7113, (20110615), pages 655 - 660, (20110112), XP028227260 [IP] 1,4-11 * page 659, paragraph l *

DOI:   http://dx.doi.org/10.1016/j.phymed.2011.01.003
 [Y]  - SAELY ET AL, "Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, (20070704), vol. 383, no. 1-2, doi:10.1016/J.CCA.2007.04.029, ISSN 0009-8981, pages 97 - 102, XP022142309 [Y] 1,4-11 * figure 1 *

DOI:   http://dx.doi.org/10.1016/j.cca.2007.04.029
 [Y]  - SRIDEVI DEVARAJ ET AL, "CRP and Adiponectin and Its Oligomers in the Metabolic Syndrome: Evaluation of New Laboratory-Based Biomarkers", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, (20080415), vol. 129, no. 5, doi:10.1309/RN84K51B2JJY1Y0B, ISSN 0002-9173, pages 815 - 822, XP055110824 [Y] 1,4-11 * page 815, column 2 *

DOI:   http://dx.doi.org/10.1309/RN84K51B2JJY1Y0B
International search[X]US2003162754  (LIGON BROOKE [US]);
 [A]US2003170239  (HERING BERNHARD J [US], et al);
 [Y]US2007128298  (COWLEY MICHAEL A [US], et al);
 [X]US2010197789  (ARIMA HIROSHI [JP], et al);
 [A]  - XU ET AL., "Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system", CELL METABOLISM, (200601), vol. 3, no. 1, pages 47 - 58, XP055110417

DOI:   http://dx.doi.org/10.1016/j.cmet.2005.11.015
Examination   - Jide Tian ET AL, "Oral Treatment with [gamma]-Aminobutyric Acid Improves Glucose Tolerance and Insulin Sensitivity by Inhibiting Inflammation in High Fat Diet-Fed Mice", PLoS ONE, (20110922), vol. 6, no. 9, doi:10.1371/journal.pone.0025338, page e25338, XP055244608

DOI:   http://dx.doi.org/10.1371/journal.pone.0025338
    - DAVID A SASS ET AL, "Nonalcoholic Fatty Liver Disease: A Clinical Review", DIGESTIVE DISEASES AND SCIENCES, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20050101), vol. 50, no. 1, doi:10.1007/S10620-005-1267-Z, ISSN 1573-2568, pages 171 - 180, XP019237111

DOI:   http://dx.doi.org/10.1007/s10620-005-1267-z
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.